

Cardiovascular Dynamics *in-silico*

Pharmacological Targeting of Long QT 3 Syndrome: Proof of Concept for an *in-silico* Drug Development Platform



Jonathan D. Moreno

MD/PhD Candidate
Colleen Clancy Laboratory
Institute for Computational Biomedicine
Weill Cornell Medical College

Outline

- Biophysics | Clinical Medicine | Cardiovascular Pharmacology | Mathematics | Engineering | HPC
- Ion-channel mutations (long QT)
 - Biophysics, genotype, phenotype and clinical characteristics
- Current treatment strategies
- *In-silico* predictive modeling and computational biomedicine
 - Formulation of Markov models of drug-receptor interactions
 - Channel | cell | cable | tissue | 3D heart
 - Numerical techniques
 - High performance computing


Ion-channel mutations and their arrhythmogenicity

- **Channelopathy:** Mutations in genes that encode ion channels can lead to abnormal channel function leading to perturbation of the AP to cause arrhythmias. Specific Na⁺ channel mutations:
 - Gain of function during AP plateau (LQT)
 - Overall loss of channel function (Brugada, ICCD, SSS)
- Hereditary Long QT (LQT) syndrome
 - Prolongation of QT interval on ECG can lead to life-threatening arrhythmias and sudden cardiac death
 - **LQT3:** Usually bradycardic; occurring during sleep or relaxation

The Long QT (3) Syndrome

- Heterogeneous group of mutations in cardiac sodium channel α subunit
 - Genetically distinct, clinical presentation similar with subtle differences
 - Overlapping syndromes with clinical characteristics coexisting in a single patient
- Δ KPQ identified in 1995
 - Transient failure of inactivation \rightarrow persistent I_{Na}
- D1790G: C terminal mutation, LQT3 clinical phenotype, possible distinct mechanism of action

Na⁺ Channel Macromolecular Complex




Institute for Computational Biomedicine | Weill Cornell Medical College of Cornell University

Ruan, 2009



5

Spectrum of Mutations in SCN5A



Institute for Computational Biomedicine | Weill Cornell Medical College of Cornell University

6



Hodgkin Huxley Formulation

- HH formulation computes conductance for each current as a function of the P(O) of a series of hypothetical gates
 - Conductance is $f(t, V)$ via gates
 - 1st order transitions from $C \rightarrow O$ and $O \rightarrow C$ that are *independent* of the other gates
 - Ions can only pass through the open state of the gate
- Based on experimental data, Na^+ activation can be modeled by 3 identical activation gates (m^3)
- Inactivation shortly after activation (h)
- LRd also includes slow inactivation gate (j)

$$I_{\text{Na}} = G_{\text{Na}} * m^3 * h * j * (V - E_{\text{Na}})$$


Markov-based Models

Motivation


- Need for models with explicit representation of single ion-channel states
- HH models are limited in their ability to describe specific aspects of single channel behavior
 - Inactivation of the Na^+ channel greater when in state O
- Assumption of independent gating ($m^3 \cdot h \cdot j$) fails
- MM can represent the dependence of a given transition on the occupancy of different states of the channel
 - Assume that transitions between channel states depend on the present conformation of the channel, but not on previous behavior

Formulating the model


- Wild Type: Use as many states as necessary to recapitulate the kinetics of channels
- Experimental data:
 - k_{on} , k_{off} rates
 - pKa – for drug partitioning
 - Steady State Availability
 - Tonic Block - $k_{d_{closed}}$
 - Use Dependent Block - $k_{d_{open}}$
 - Frequency dependence of UDB
 - Recovery from UDB
- Models adhere to 2nd law of thermodynamics (microscopic reversibility)
- Start playing!



Wild Type Formulation



Δ KPQ Channel with Bursting States



Runge Kutta Formulation

Forward Euler
- Error $O(h^1)$

$$y_{n+1} = y_n + h * f(x_n, y_n)$$

Fourth Order Runge Kutta
- Error $O(h^4)$

$$\frac{dy}{dt} = f(t, y)$$

$$k_1 = h * f(t_n, y_n)$$

$$k_2 = h * f\left(t_n + \frac{h}{2}, y_n + \frac{k_1}{2}\right)$$

$$k_3 = h * f\left(t_n + \frac{h}{2}, y_n + \frac{k_2}{2}\right)$$

$$k_4 = h * f(t_n + h, y_n + k_3)$$

$$y_{n+1} = y_n + \frac{k_1}{6} + \frac{k_2}{3} + \frac{k_3}{3} + \frac{k_4}{6} + Error$$

...some code

```

;Drug Free States
k1_O = hN1a1*Cell_pr->mC1 + b2*Cell_pr->mIF + koff*Cell_pr->DmO + k_off*Cell_pr->DmO + b1*Cell_pr->mO5 + mu2*Cell_pr->mBO - Cell_pr->mO*(b13 + a2 + mu1 + kon + k_on + ax1);
k1_C1 = hN1a2*Cell_pr->mC1 + a3*Cell_pr->mIF + b13*Cell_pr->mC1 + mu2*Cell_pr->mBC1 + koff*Cell_pr->DmC1 + k_off*Cell_pr->DmC1 - Cell_pr->mC1*(b12 + b3 + a13 + mu1 + kon + k_on);
k1_C2 = hN1a1*Cell_pr->mC1 + a3*Cell_pr->mC2 + b12*Cell_pr->mC1 + mu2*Cell_pr->mBC2 + koff*Cell_pr->DmC2 + k_off*Cell_pr->DmC2 - Cell_pr->mC2*(b11 + b3 + a12 + mu1 + kon + k_on);
k1_C3 = hN1a3*Cell_pr->mC1 + b11*Cell_pr->mC2 + mu2*Cell_pr->mBC3 + koff*Cell_pr->DmC3 + k_off*Cell_pr->DmC3 - Cell_pr->mC3*(b3 + a11 + mu1 + kon + k_on);
k1_C3 = hN1a3*Cell_pr->mC3 + b11*Cell_pr->mC2 + mu2*Cell_pr->mBC3 + koff*Cell_pr->DmC3 + k_off*Cell_pr->DmC3 - Cell_pr->mC3*(b3 + a11 + mu1 + kon + k_on);
k1_IF = hN1a1*Cell_pr->mC2 + b3*Cell_pr->mC2 + b12*Cell_pr->mIF + k_on*Cell_pr->DmC2 - Cell_pr->mC2*(b11 + a3 + a12 + k_on);
k1_IF = hN1a1*Cell_pr->mC2 + b3*Cell_pr->mC1 + a4*Cell_pr->mM1 + a2*Cell_pr->mO + k_on*Cell_pr->DmIF - Cell_pr->mIF*(b12 + b2 + a3 + a4 + k_on);
k1_M1 = hN1a4*Cell_pr->mIF + b5*Cell_pr->mM2 - Cell_pr->mM1*(b4 + a5);
k1_M2 = hN1a5*Cell_pr->mM1 - Cell_pr->mM2*(b5);

k1_O5 = hN1a6*Cell_pr->mO + k_on*Cell_pr->DmO5 - Cell_pr->mO5*(b6 + k_on);
k1_BC3 = hN1a6*Cell_pr->mC3 + b11*Cell_pr->mBC2 + koff*Cell_pr->DmBC3 + k_off*Cell_pr->DmBC3 - Cell_pr->mBC3*(mu2 + a11 + kon + k_on);
k1_BC2 = hN1a6*Cell_pr->mC2 + a11*Cell_pr->mBC3 + b12*Cell_pr->mBC1 + koff*Cell_pr->DmBC2 + k_off*Cell_pr->DmBC2 - Cell_pr->mBC2*(mu2 + b11 + a12 + kon + k_on);
k1_BC1 = hN1a6*Cell_pr->mC1 + a12*Cell_pr->mBC2 + b12*Cell_pr->mBO + koff*Cell_pr->DmBC1 + k_off*Cell_pr->DmBC1 - Cell_pr->mBC1*(mu2 + b12 + a13 + kon + k_on);
k1_BO = hN1a1*Cell_pr->mO + a13*Cell_pr->mBC1 + koff*Cell_pr->DmBO + k_off*Cell_pr->DmBO - Cell_pr->mBO*(mu2 + b13 + kon + k_on);

;Charged Drug Bound States
k1_DO = hN1a6*Cell_pr->mO + a13*Cell_pr->DmC1 + b11*Cell_pr->DmO5 + b22*Cell_pr->DmIF + mu2*Cell_pr->DmBO - Cell_pr->DmO*(koff + b13e + a22 + a21 + mu1);
k1_DC1 = hN1a6*Cell_pr->mC1 + a12*Cell_pr->DmC2 + a33*Cell_pr->DmIF + b13*Cell_pr->DmO + mu2*Cell_pr->DmBC1 - Cell_pr->DmC1*(koff + b12 + a33 + a32 + mu1);
k1_DC2 = hN1a6*Cell_pr->mC2 + a11*Cell_pr->DmC3 + a33*Cell_pr->DmC2 + b12*Cell_pr->DmC1 + mu2*Cell_pr->DmBC2 - Cell_pr->DmC2*(koff + b11 + b33 + a12 + mu1);
k1_DC3 = hN1a6*Cell_pr->mC3 + b11*Cell_pr->DmC2 + a33*Cell_pr->DmC3 + mu2*Cell_pr->DmBC3 - Cell_pr->DmC3*(koff + b33 + a11 + mu1);
k1_DO5 = hN1a1*Cell_pr->DmO + b11*Cell_pr->DmC2;
k1_DI3 = hN1a33*Cell_pr->DmC3 + b11*Cell_pr->DmC2 - Cell_pr->DmC3*(a11 + a33);
k1_DI2 = hN1a33*Cell_pr->DmC2 + a11*Cell_pr->DmC3 + b12*Cell_pr->DmIF - Cell_pr->DmC2*(a33 + b11 + a12);
k1_DIF = hN1a33*Cell_pr->DmC1 + a12*Cell_pr->DmC2 + b44*Cell_pr->DmM1 + a22*Cell_pr->DmO - Cell_pr->DmIF*(a33 + b12 + a44 + b22);
k1_DM1 = hN1a44*Cell_pr->DmIF + b55*Cell_pr->DmM2 - Cell_pr->DmM1*(a4 + a55);
k1_DM2 = hN1a55*Cell_pr->DmM1 + b55*Cell_pr->DmM2;
k1_DBO = hN1a6*Cell_pr->mO + a13*Cell_pr->DmBC1 + mu1*Cell_pr->DmO - Cell_pr->DmBO*(koff + b13 + mu2);
k1_DBC1 = hN1a6*Cell_pr->mBC1 + a12*Cell_pr->DmBC2 + b12*Cell_pr->DmC1 + mu1*Cell_pr->DmC2 - Cell_pr->DmBC1*(koff + b12 + a13 + mu2);
k1_DBC2 = hN1a6*Cell_pr->mBC2 + a11*Cell_pr->DmBC3 + b12*Cell_pr->DmBC1 + mu1*Cell_pr->DmC2 - Cell_pr->DmBC2*(koff + b11 + a12 + mu2);
k1_DBC3 = hN1a6*Cell_pr->mBC3 + b11*Cell_pr->DmBC2 + mu1*Cell_pr->DmC3 - Cell_pr->DmBC3*(koff + a11 + mu2);

;Initial Drug Bound States
k1_D_O = hN1a6*Cell_pr->mO + a13*Cell_pr->DmC1 + b_22*Cell_pr->DmIF + b2*Cell_pr->DmO5 + mu2*Cell_pr->DmBO - Cell_pr->DmO*(koff + b13 + a_22 + a2 + mu1);
k1_D_C1 = hN1a6*Cell_pr->mC1 + a12*Cell_pr->DmC2 + a_33*Cell_pr->DmIF + b13*Cell_pr->DmO + mu2*Cell_pr->DmBC1 - Cell_pr->DmC1*(koff + b12 + b_33 + a13 + a2 + mu1);
k1_D_C2 = hN1a6*Cell_pr->mC2 + a11*Cell_pr->DmC3 + a_33*Cell_pr->DmC2 + b12*Cell_pr->DmC1 + mu2*Cell_pr->DmBC2 - Cell_pr->DmC2*(koff + b11 + b_33 + a12 + mu1);
k1_D_C3 = hN1a6*Cell_pr->mC3 + a_33*Cell_pr->DmC3 + b11*Cell_pr->DmC2 + mu2*Cell_pr->DmBC3 - Cell_pr->DmC3*(koff + b_33 + a11 + mu1);
k1_D_O5 = hN1a1*Cell_pr->DmO + k_on*Cell_pr->DmO5 - Cell_pr->DmO5*(b6 + k_on);
k1_D_I3 = hN1a33*Cell_pr->DmC3 + b11*Cell_pr->DmC2 + k_on*Cell_pr->DmC3 - Cell_pr->DmC3*(a_33 + a11 + k_on);
k1_D_I2 = hN1a33*Cell_pr->DmC2 + a11*Cell_pr->DmC3 + b12*Cell_pr->DmIF + k_on*Cell_pr->DmIF - Cell_pr->DmC2*(a_33 + b11 + a12 + k_on);
k1_D_IF = hN1a33*Cell_pr->DmC1 + a12*Cell_pr->DmC2 + a_22*Cell_pr->DmO + k_on*Cell_pr->DmIF - Cell_pr->DmIF*(a_33 + b12 + a44 + b22);
k1_D_BO = hN1a6*Cell_pr->mO + a13*Cell_pr->DmBC1 + mu1*Cell_pr->DmO - Cell_pr->DmBO*(koff + b13 + mu2);
k1_D_BC1 = hN1a6*Cell_pr->mBC1 + a12*Cell_pr->DmBC2 + b12*Cell_pr->DmC1 + mu1*Cell_pr->DmC2 - Cell_pr->DmBC1*(koff + b12 + a13 + mu2);
k1_D_BC2 = hN1a6*Cell_pr->mBC2 + a11*Cell_pr->DmBC3 + b12*Cell_pr->DmBC1 + mu1*Cell_pr->DmC2 - Cell_pr->DmBC2*(koff + b11 + a12 + mu2);
k1_D_BC3 = hN1a6*Cell_pr->mBC3 + b11*Cell_pr->DmBC2 + mu1*Cell_pr->DmC3 - Cell_pr->DmBC3*(koff + a11 + mu2);
    
```

The failure of antiarrhythmics

- Sudden Cardiac Death is the #1 cause of death in the US, CVD in general will be global cause of death by 2020
- CAST, CAST II trials:
 - an incomplete understanding and inability to predict interaction of intrinsically complex drug pharmacology with complexity of cardiac tissue
 - Drug receptor dynamics
 - Anatomical and electrical heterogeneity
 - Mutant channel interactions
- Off target effects of noncardiovascular therapeutics
 - 40% of all new pharmaceuticals affect repolarization process
 - Vast majority of drugs pulled off market (Vioxx)
 - Side effects may occur <1% of patient population
 - Predict vulnerable populations?
 - Discard compounds earlier in the product development pipeline?
 - 50:1 failure to success rate

"All you have to do is to decrease our attrition rate from around 98% to 90% and you would make us twice as successful."

Cardiovascular Dynamics *in-silico*

- Single channel → single cell → 1D fiber → 2,3D tissues
 - *Spatiotemporal trends that emerge in higher dimensions that allow for propagation of arrhythmia are missed at smaller spatial scales*
- Develop a computational framework for an *in-silico* drug screen of cardiovascular medications
 - Predictive simulations of pharmacodynamics in an engineered virtual cardiac tissue
 - Identification of key parameters for drug-receptor dynamics

Biophysics and
experimental data

Computational and
engineering methods




Model “wish list”

- Transport phenomena: Diffusion
- Kinetics of drug receptor interactions
- Macroscopic wave propagation
- Scalability: 0D → 3D
- Optimize with high performance computing
 - Numerical optimizations
 - Parallel computations
 - GPGPU

Sodium Channel Block Subclassification

- Class IA (e.g., **quinidine**)
 - Moderate Na⁺ channel blockade
 - ↑ ERP
- Class IB (e.g., **lidocaine**)
 - Weak Na⁺ channel blockade
 - ↓ ERP
- Class IC (e.g., **flecainide**)
 - Strong Na⁺ channel blockade
 - → ERP



Antiarrhythmics

Flecainide

- Class 1C antiarrhythmic
- pKa ~ 9.3
- 99% charged at physiologic pH

Lidocaine

- Class 1B antiarrhythmic
- pKa ~ 7.6
- 50% charged at physiologic pH

